Retension Pharmaceuticals, Inc.
Research Retension Pharmaceuticals, Inc. (RTSN) on Bullrun: market cap USD 87.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRTSN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 87.01M
- Financial periodQ2 2026
Valuation Snapshot
latest market cap is USD 87.01M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 6.30M | -USD 7.78M | n/a | -1.38 | USD 18.90M | n/a | -USD 7.78M |
| FY2024 | USD 0 | -USD 1.91M | -USD 1.76M | n/a | -0.42 | USD 8.19M | n/a | -USD 1.73M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 87.01M | n/a | n/a | n/a |
About Retension Pharmaceuticals, Inc.
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Retension Pharmaceuticals, Inc.'s market cap?
Retension Pharmaceuticals, Inc.'s market capitalization is USD 87.01M.
What does Retension Pharmaceuticals, Inc. do?
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.